FAPI PET/CT在肿瘤学研究中的诊断准确性评估:系统评价与荟萃分析
该系统评价与荟萃分析纳入39项研究共1259例患者,评估FAPI PET/CT对原发灶、淋巴结转移和远处转移的诊断准确性。基于患者的分析显示,原发灶 pooled 灵敏度为0.99(95%CI 0.97-1.0),淋巴结转移为0.91(95%CI 0.81-0.96),远处转移为0.99(95%CI 0.96-1.0)。配对分析中FAPI对原发灶、淋巴结和转移灶的灵敏度均高于[18F]FDG PET/CT(均P<0.001)。作者结论认为FAPI PET/CT诊断性能优于[18F]FDG,但仍需进一步研究以评估其在特定癌症类型和临床环境中的效用和适应证。
要点
- FAPI PET/CT对原发灶 pooled 灵敏度0.99(95%CI 0.97-1.0),淋巴结转移0.91(95%CI 0.81-0.96),远处转移0.99(95%CI 0.96-1.0)。
- 配对分析中FAPI对原发灶、淋巴结和转移灶的灵敏度均高于[18F]FDG PET/CT,差异有统计学意义(均P<0.001)。
- 异质性方面,原发灶分析受中度影响,远处转移分析受高度影响,淋巴结转移分析异质性可忽略。
核心结论
- FAPI PET/CT对原发灶、淋巴结转移和远处转移的诊断性能优于[18F]FDG PET/CT。
- 作者指出仍需进一步研究以更好地评估FAPI在特定癌症类型和临床环境中的效用和适应证。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE、Embase、Scopus、PubMed、Cochrane Central Register of Controlled Trials、相关试验注册库和参考文献。
- 纳入39项研究共1259例患者,评估FAPI PET/CT的诊断准确性。
- 两名作者独立筛选文献并提取数据,采用QUADAS-2标准评估研究质量。
- 对每项研究计算原发灶、淋巴结转移和远处转移的灵敏度、特异度及95%CI,采用随机效应模型合并数据并评估异质性(I²指数)。
主要发现
- 基于患者的分析中,FAPI PET/CT检测原发灶的 pooled 灵敏度为0.99(95%CI 0.97-1.0)。
- FAPI PET/CT检测淋巴结转移的 pooled 灵敏度为0.91(95%CI 0.81-0.96),检测远处转移的 pooled 灵敏度为0.99(95%CI 0.96-1.0)。
- FAPI与[18F]FDG PET/CT的配对分析显示,FAPI检测原发灶、淋巴结转移和转移灶的灵敏度均更高(均P<0.001),差异有统计学意义。
- 异质性分析显示原发灶分析受中度影响,远处转移分析受高度影响,淋巴结转移分析异质性可忽略。
关键数值与推荐
- FAPI PET/CT检测原发灶 pooled 灵敏度0.99(95%CI 0.97-1.0)。
- FAPI PET/CT检测淋巴结转移 pooled 灵敏度0.91(95%CI 0.81-0.96)。
- FAPI PET/CT检测远处转移 pooled 灵敏度0.99(95%CI 0.96-1.0)。
- FAPI与[18F]FDG PET/CT配对分析中,FAPI检测原发灶、淋巴结和转移灶的灵敏度均更高(均P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原发灶分析的异质性受中度影响。
- 远处转移分析的异质性受高度影响。
- 作者指出仍需进一步研究以更好地评估FAPI在特定癌症类型和临床环境中的效用和适应证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fibroblast-activation protein is a promising target for oncologic molecular imaging. Studies show that fibroblast activation protein inhibitor (FAPI) radiotracers are accurate diagnostics with favorable tumor-to-background ratios across various cancers. Therefore, we performed a systematic review and metaanalysis to assess the diagnostic performance of FAPI PET/CT in comparison with [18F]FDG PET/CT, the most widely used radiotracer in oncology. Methods: We conducted a systematic search in MEDLINE, Embase, Scopus, PubMed, Cochrane Central Register of Controlled Trials, relevant trial registries, and bibliographies. The search consisted of combinations of terms for 3 topics: neoplasia, PET/CT, and FAPI. Two authors independently screened retrieved articles using predefined inclusion and exclusion criteria and extracted the data. Study quality was assessed using the criteria of QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies 2). For each study, the sensitivity, specificity, and 95% CIs were calculated to determine diagnostic accuracy for primary, nodal, and metastatic lesions. A random-effects metaanalysis was used for pooling the data, and heterogeneity was assessed (I2 index). Results: Thirty-nine studies (1,259 patients) investigating the use of FAPI PET/CT were included. On a patient-based analysis, pooled sensitivity was 0.99 (95% CI, 0.97-1.0) for the detection of primary lesions. Pooled sensitivity for nodal and distant metastases was 0.91 (95% CI, 0.81-0.96) and 0.99 (95% CI, 0.96-1.0), respectively. On a paired analysis between FAPI and [18F]FDG PET/CT, FAPI had a higher sensitivity in the detection of primary, nodal, and metastatic lesions (all P < 0.001). The differences in sensitivities between FAPI and [18F]FDG were statistically significant. In terms of heterogeneity, analyses on primary lesions were moderately affected, distant metastatic lesions were highly affected, and the nodal metastatic analyses had negligible heterogeneity. Conclusion: The diagnostic performance of FAPI PET/CT is superior to that of [18F]FDG in the detection of primary, nodal, and distant metastases. However, further studies are needed to better evaluate its utility and indication in specific cancer types and clinical settings.
引用
- Wass G, Clifford K, Subramaniam RM, et al. Evaluation of the Diagnostic Accuracy of FAPI PET/CT in Oncologic Studies: Systematic Review and Metaanalysis. J Nucl Med. 2023. PMID: 37290798. doi:10.2967/jnumed.123.265471
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。